Switching to a longer-acting tacrolimus after liver transplant
Part of Digestive system clinical trials.
This trial tests if switching from a standard twice-daily tacrolimus to a once-daily prolonged-release version is safe and effective for liver transplant recipients who have stable liver function. It aims to simplify your medication schedule.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You had a liver transplant at least 3 months ago
- You have been on a stable dose of standard (immediate-release) tacrolimus for the past month
- Your liver enzyme levels (AST and ALT) are in the normal range
- You are not currently taking a long-acting tacrolimus
- You have not had any organ rejection in the past month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking immunosuppressive drugs (tacrolimus and mycophenolate mofetil) just once a day, instead of twice, works as well for people who recently had a liver transplant. The goal is to make the medication schedule easier and possibly safer.
This study compares immediate-release versus extended-release tacrolimus (an anti-rejection medicine) to see if one form causes fewer tremors after a first liver transplant. It may help you and your care team choose the best form if tremors are a problem while your body adjusts after transplant.
This trial tests if switching from a standard anti-rejection medicine to everolimus is safe and effective for liver transplant patients. It may help protect kidney function while preventing organ rejection.
This study tests an extended-release version of the anti-rejection drug tacrolimus in children who have already had a stable liver transplant. The goal is to see if the longer-acting capsule works as well as the immediate-release form, potentially simplifying daily medication routines.
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
This non-interventional study looks at how tacrolimus blood levels relate to transplant effectiveness and side effects. It uses your existing medical data to understand whether tacrolimus behaves differently from person to person and how that links to safety.
Hear when a new Liver Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.